- November 22, 2026
- Updated 8:26 am
Study Suggests Spironolactone May Help Lower Blood Pressure in Stroke Survivors
- 94 Views
- admin
- November 16, 2026
- Health Public Health
A new study highlights a low-cost medication that could aid stroke survivors in controlling blood pressure. The research, referred to as the REDUCE trial, examines whether spironolactone, known as a water pill, might effectively reduce high blood pressure following a stroke. The findings were shared at the American Heart Association’s Scientific Sessions held on November 6-9, 2026, in Chicago.
Study Design and Findings
The REDUCE trial split participants into two distinct groups: one group added spironolactone to their existing treatment regimen, while the other adhered to conventional post-stroke care. The research tracked blood pressure levels at home over six months to discern any differences brought by spironolactone.
After three months, those taking spironolactone saw an average reduction of about eight points in systolic blood pressure, with results showing an average of 126 compared to 133 in the usual care group. Furthermore, 52% of participants on spironolactone achieved the recommended blood pressure target of less than 130/80, in contrast to 30% of those under standard care.
“Lowering blood pressure is paramount for preventing another stroke, yet many struggle to meet targets post-stroke,” noted Dr. Jordana Cohen, co-lead author and associate professor at the University of Pennsylvania.
Dr. Cohen emphasized that adding spironolactone resulted in a significant blood pressure decrease, potentially reducing future stroke and heart attack risks.
Expert Opinions and Considerations
Dr. Alfred Joshua, while acknowledging the promising results of the study, noted that its scope did not extend to confirming whether spironolactone prevents further strokes. The focus remained on blood pressure metrics alone. Spironolactone aids in eliminating excess salt and water but retains potassium. This requires monitoring to prevent adverse effects, especially for those with kidney issues or those taking specific supplements.
Joshua advised patients with persistent high blood pressure post-stroke to consult their healthcare provider about the suitability of spironolactone, citing concerns such as dizziness and high potassium risks.
Study Limitations
The trial concluded early with only 160 participants instead of the intended 200. Moreover, 15% of participants lacked blood pressure data at the three-month checkpoint. Notably, spironolactone users were on more blood pressure medications than those receiving typical care.
Larger, more extensive studies are necessary to determine if spironolactone can prevent additional strokes or heart attacks, the researchers concluded.